Platelet Rich Plasma in Treatment of Melasma

A

Assiut University

Status and phase

Unknown
Phase 3

Conditions

Platelet Rich Plasma
Melasma

Treatments

Biological: Platelet rich plasma

Study type

Interventional

Funder types

Other

Identifiers

NCT03308370
ETEPRPM

Details and patient eligibility

About

Melasma is a common acquired disorder characterized by symmetric, hyperpigmented patches with an irregular outline, occurring most commonly on the face. The therapy for melasma has always been challenging and discouraging. Platelet rich plasma has been used over the last several years as an effective treatment in various surgical and medical fields. In recent years, Platelet rich plasma has also started to be used in the field of cosmetology. This study is designed to evaluate the therapeutic effect of platelet rich plasma in melasma.

Full description

Melasma is a pigmentary disorder that can be disfiguring and can cause to significant emotional stresses for sufferers, for which a universally effective treatment is still lacking. Platelet rich plasma is commonly used in dermatology and plastic surgery, especially for treating chronic wounds, ulcers, and burns. The most important contents of platelets are contained in the α-granules. Some of the bioactive substances present in the α-granules include platelet-derived growth factor, transforming growth factor -β1 and -β2epidermal growth factor, and mitogenic growth factors such as platelet-derived angiogenesis factor and fibrinogen. transforming growth factor -β1 decreases melanogenesis via delayed extracellular signal-regulated kinase activation. The regression of melasma in a 27-years-old woman after injecting platelet rich plasma for skin rejuvenation was observed, but controlled clinical trials are still lacking to confirm this preliminary observation.

Enrollment

26 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with melasma 18 years old or more

Exclusion criteria

  • Patients less than 18 years.
  • Pregnant females and females on oral contraceptive pills.
  • Patients with a history of hypertrophic scars or keloids.
  • Patients with recurrent herpes infection or with present cutaneous infection and those with facial cancer.
  • Patients with blood disorders and platelet abnormalities and chronic liver disease.
  • Patients using systemic chemotherapy, anticoagulation therapy and antiplatelet agents.

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

26 participants in 1 patient group

Platelet rich plasma
Experimental group
Description:
intradermal injection of 5 ml of autologous platelet rich plasma in the lesional skin of the face of 20 melasma patients every 4 weeks for 3 times
Treatment:
Biological: Platelet rich plasma

Trial contacts and locations

0

Loading...

Central trial contact

Amira A Abdel Motaleb, PHD; Eman R Hofny, PHD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems